Agios Pharmaceuticals, Inc.
AGIO
$29.20
-$1.03-3.41%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 55.02% | 3.41% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 55.02% | 3.41% | |||
| Cost of Revenue | 1.65% | -5.52% | |||
| Gross Profit | 7.44% | 6.89% | |||
| SG&A Expenses | 25.04% | -10.02% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 9.09% | -7.00% | |||
| Operating Income | -4.03% | 8.02% | |||
| Income Before Tax | -5.44% | 7.67% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -4.45% | 7.67% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -4.45% | 7.67% | |||
| EBIT | -4.03% | 8.02% | |||
| EBITDA | -4.17% | 8.19% | |||
| EPS Basic | -4.08% | 7.99% | |||
| Normalized Basic EPS | -5.05% | 7.99% | |||
| EPS Diluted | -4.02% | 7.94% | |||
| Normalized Diluted EPS | -5.05% | 7.99% | |||
| Average Basic Shares Outstanding | 0.36% | 0.36% | |||
| Average Diluted Shares Outstanding | 0.36% | 0.36% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||